Feature

FDA approves subcutaneous immunoglobulin treatment for CIDP

The Food and Drug Administration has approved Hizentra as the first subcutaneously administered human immunoglobulin maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a statement from its manufacturer, CSL Behring.

Immune globulin subcutaneous (human) 20% liquid (Hizentra) was approved at doses of 0.2 and 0.4 g/kg per week because of the strength of the phase 3 PATH (Polyneuropathy and Treatment with Hizentra) clinical trial and the PATH extension study, which is still ongoing. PATH is the largest and longest running randomized study of patients with CIDP. The clinical trial studied the safety, efficacy, and tolerability of the two different doses of the subcutaneous immunoglobulin in 172 patients.

FDA icon
CIDP is a rare autoimmune disease that affects the peripheral nerves and can cause permanent damage by degrading the myelin sheath, the fatty sheath along many nerve fibers. This can eventually lead to changes in activity levels and a decrease in the quality of life. Approximately 30% of patients with CIDP patients will require a wheelchair at some point in their lives if they do not receive treatment, the manufacturer said in its announcement.

There were markedly lower rates of CIDP relapse or withdrawal for any reason during Hizentra treatment among patients taking a high dose of 0.4 g/kg weekly (39%; P less than .001) and those taking a low dose of 0.2 g/kg weekly (33%; P less than .007), compared with those among patients taking placebo (63%). The adverse reactions that occurred in 5% or more of patients included local infusion-site reactions, headache, diarrhea, fatigue, and upper respiratory tract infections.

Pages

Recommended Reading

Edaravone: Costs versus benefits
MDedge Neurology
Rare neurological complication linked to Waldenstrom disease
MDedge Neurology
Cardiosphere-derived cells may reverse Duchenne heart scarring
MDedge Neurology
Conference News Roundup—American Heart Association
MDedge Neurology
FDA cites manufacturer of autologous stem cells for regulatory, manufacturing missteps
MDedge Neurology
Genetic Screens Yield Potential Therapies for Neurodegenerative Diseases
MDedge Neurology
C7 Nerve Transfer May Reduce Spastic Arm Paralysis
MDedge Neurology
Mogamulizumab active in HTLV-1–associated myelopathy
MDedge Neurology
Conference News Roundup—Association of Academic Physiatrists
MDedge Neurology
The case for being open-minded about medical marijuana
MDedge Neurology